News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
393,944 Results
Type
Article (26335)
Company Profile (60)
Press Release (367547)
Multimedia
Podcasts (34)
Webinars (7)
Section
Business (104371)
Career Advice (455)
Deals (16887)
Drug Delivery (53)
Drug Development (47732)
Employer Resources (47)
FDA (12348)
Job Trends (8484)
News (186334)
Policy (19523)
Tag
2027 Biotech Bay Standard (1)
2027 Pharm Country Standard (1)
Academia (1757)
Accelerated approval (14)
Adcomms (10)
Allergies (114)
Alliances (26824)
ALS (97)
Alzheimer's disease (978)
Antibody-drug conjugate (ADC) (162)
Approvals (12683)
Artificial intelligence (308)
Autoimmune disease (93)
Automation (8)
Bankruptcy (142)
Best Places to Work (6891)
BIOSECURE Act (5)
Biosimilars (73)
Biotechnology (40)
Bladder cancer (124)
Brain cancer (37)
Breast cancer (416)
Cancer (3078)
Cardiovascular disease (266)
Career advice (416)
Career pathing (15)
CAR-T (134)
CDC (26)
Celiac Disease (2)
Cell therapy (366)
Cervical cancer (26)
Clinical research (42959)
Collaboration (864)
Compensation (275)
Complete response letters (16)
COVID-19 (1554)
CRISPR (35)
C-suite (497)
Cystic fibrosis (59)
Data (4252)
Decentralized trials (2)
Denatured (20)
Depression (93)
Diabetes (318)
Diagnostics (3719)
Digital health (30)
Diversity (7)
Diversity, equity & inclusion (13)
Drug discovery (95)
Drug pricing (91)
Drug shortages (22)
Duchenne muscular dystrophy (125)
Earnings (38633)
Editorial (29)
Employer branding (6)
Employer resources (47)
Events (54208)
Executive appointments (590)
FDA (14642)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (6)
Frontotemporal dementia (10)
Funding (758)
Gene editing (75)
Generative AI (21)
Gene therapy (261)
GLP-1 (543)
Government (3143)
Grass and pollen (4)
Guidances (229)
Healthcare (12212)
HIV (39)
Huntington's disease (20)
IgA nephropathy (50)
Immunology and inflammation (83)
Immuno-oncology (27)
Indications (72)
Infectious disease (1689)
Inflammatory bowel disease (110)
Inflation Reduction Act (7)
Influenza (54)
Intellectual property (119)
Interviews (40)
IPO (7072)
IRA (23)
Job creations (1846)
Job search strategy (381)
JPM (19)
Kidney cancer (10)
Labor market (35)
Layoffs (195)
Leadership (8)
Legal (3646)
Liver cancer (66)
Longevity (7)
Lung cancer (486)
Lymphoma (252)
Machine learning (16)
Management (17)
Manufacturing (291)
MASH (107)
Medical device (13304)
Medtech (13350)
Mergers & acquisitions (10327)
Metabolic disorders (759)
Multiple sclerosis (100)
NASH (11)
Neurodegenerative disease (163)
Neuropsychiatric disorders (42)
Neuroscience (1701)
NextGen: Class of 2026 (3933)
Non-profit (2837)
Now hiring (35)
Obesity (314)
Opinion (96)
Ovarian cancer (120)
Pain (141)
Pancreatic cancer (140)
Parkinson's disease (164)
Partnered (17)
Patents (225)
Patient recruitment (355)
Peanut (43)
People (35663)
Pharmaceutical (15)
Pharmacy benefit managers (16)
Phase 1 (12344)
Phase 2 (18585)
Phase 3 (15265)
Pipeline (3110)
Policy (126)
Postmarket research (1668)
Preclinical (3800)
Press Release (18)
Prostate cancer (179)
Psychedelics (26)
Radiopharmaceuticals (178)
Rare diseases (433)
Real estate (2869)
Recruiting (19)
Regulatory (15711)
Reports (18)
Research institute (1656)
Resumes & cover letters (49)
Rett syndrome (16)
RNA editing (5)
RSV (39)
Schizophrenia (113)
Series A (116)
Series B (94)
Service/supplier (2)
Sickle cell disease (45)
Special edition (6)
Spinal muscular atrophy (104)
Sponsored (16)
Startups (2134)
Stomach cancer (11)
Supply chain (60)
Tariffs (25)
The Weekly (14)
Vaccines (507)
Venture capital (28)
Weight loss (211)
Women's health (56)
Worklife (4)
Date
Today (71)
Last 7 days (340)
Last 30 days (1103)
Last 365 days (16203)
2026 (1667)
2025 (16468)
2024 (19847)
2023 (22735)
2022 (30680)
2021 (32985)
2020 (32190)
2019 (28412)
2018 (21811)
2017 (18905)
2016 (18111)
2015 (21194)
2014 (16024)
2013 (13241)
2012 (14349)
2011 (14622)
2010 (13181)
Location
Africa (367)
Alabama (30)
Alaska (2)
Arizona (176)
Arkansas (10)
Asia (25503)
Australia (4029)
California (5592)
Canada (1915)
China (792)
Colorado (287)
Connecticut (286)
Delaware (249)
Europe (49914)
Florida (951)
Georgia (225)
Hawaii (1)
Idaho (35)
Illinois (580)
India (32)
Indiana (380)
Iowa (11)
Japan (320)
Kansas (90)
Kentucky (19)
Louisiana (18)
Maine (28)
Maryland (895)
Massachusetts (3761)
Michigan (151)
Minnesota (443)
Mississippi (5)
Missouri (80)
Montana (19)
Nebraska (21)
Nevada (65)
New Hampshire (73)
New Jersey (1935)
New Mexico (10)
New York (1575)
North Carolina (820)
North Dakota (4)
Northern California (2656)
Ohio (214)
Oklahoma (8)
Oregon (28)
Pennsylvania (1359)
Puerto Rico (12)
Rhode Island (35)
South America (523)
South Carolina (59)
Southern California (2246)
Tennessee (126)
Texas (1025)
United States (21724)
Utah (194)
Virginia (142)
Washington D.C. (52)
Washington State (386)
West Virginia (4)
Wisconsin (71)
Wyoming (1)
393,944 Results for "kahr medical".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
Myeloma Investment Fund Invests in KAHR to Explore Potential of KAHR’s Lead Immunotherapy Drug Candidate for the Treatment of Multiple Myeloma
KAHR and the Myeloma Investment Fund announced that the MIF has invested in KAHR to explore the potential of DSP107, KAHR’s lead immunotherapy drug candidate, for the treatment of multiple myeloma.
November 17, 2022
·
4 min read
Drug Development
KAHR Reports Dose Escalation Results from Phase I Trial of DSP107 in Combination with anti-PD-L1 in Patients with Advanced Solid Tumors
KAHR today announced positive results from the dose escalation Phase I study of DSP107 in combination with atezolizumab (anti-PD-L1) in patients with advanced solid tumors.
May 31, 2023
·
4 min read
Press Releases
Medical-imaging company Imagion Biosystems Lodges IND with FDA for Phase 2 Trial of MagSense® HER2 targeted imaging agent
February 4, 2026
·
2 min read
Business
KAHR Announces Appointment of Jennifer Minai-Azary to its Board of Directors
KAHR , a clinical-stage cancer immunotherapy company developing novel bi-functional fusion proteins, today announced the appointment of Jennifer Minai-Azary to its Board of Directors. The appointment is effective immediately.
July 11, 2022
·
2 min read
Samsung Biologics and KAHR Medical Announce Development and Manufacturing Agreement for Cancer Immunotherapy Drug Candidate
Samsung Biologics, the world’s leading contract development and manufacturing organization, signed a strategic partnership with KAHR Medical Ltd., a cancer immunotherapy company developing novel multifunctional immune-recruitment proteins.
June 2, 2021
·
3 min read
Press Releases
Intricon becomes Forj Medical and Announces Opening Plans for its Advanced Manufacturing Facility in Costa Rica
Intricon completes construction of its Evolution Free Zone location, combines with Minnetronix Medical, and will fly the Forj Medical flag at its new site; equipment and workforce move into place for the grand opening
December 9, 2025
·
1 min read
KAHR Medical to Present at Oppenheimer’s Private Life Sciences Company Call Series
KAHR Medical today announced the company’s participation in Oppenheimer’s Private Life Sciences Company Call Series taking place virtually August 17-19, 2020.
August 13, 2020
·
2 min read
Press Releases
Turn Therapeutics Enters Global Supply, Development, and License Agreement with Leading Medical-Surgical Product Manufacturer and Distributor Medline
October 31, 2025
·
3 min read
Press Releases
Seno Medical’s Next-Generation Imagio® Imaging System Obtains European Union (EU) Medical Device Regulation (MDR) CE Mark Certification
January 29, 2026
·
3 min read
Drug Development
KAHR and Cancer Focus Fund Announce First Patient Dosed in Phase 1b Clinical Trial of Anti-CD47 Product Candidate DSP107 in Blood Cancers
KAHR, today announced that the first patient has been dosed in a Phase 1b clinical trial of DSP107.
February 17, 2022
·
5 min read
1 of 39,395
Next
